Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APLIFNASDAQ:ENSCNASDAQ:MBIONASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLIFAppili Therapeutics$0.01$0.02$0.01▼$0.03$1.29M-0.639,415 shsN/AENSCEnsysce Biosciences$2.02-5.2%$2.31$1.62▼$14.67$4.79M0.97948,782 shs42,900 shsMBIOMustang Bio$1.05-1.9%$1.21$1.01▼$34.00$4.60M2.24208,094 shs101,418 shsMYNZMainz Biomed$1.43-6.5%$2.45$1.42▼$22.40$4.92M0.3133,430 shs60,754 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLIFAppili Therapeutics0.00%-14.15%-17.50%-57.76%-65.67%ENSCEnsysce Biosciences-5.16%-2.42%-9.42%-41.45%-75.61%MBIOMustang Bio-1.87%-10.26%-11.76%-25.00%-97.53%MYNZMainz Biomed-6.54%-21.86%-31.58%-68.78%-93.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENSCEnsysce Biosciences0.2568 of 5 stars0.04.00.00.00.00.00.6MBIOMustang Bio0.1264 of 5 stars0.03.00.00.00.00.00.6MYNZMainz Biomed2.465 of 5 stars3.35.00.00.00.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLIFAppili Therapeutics 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00879.02% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLIFAppili Therapeutics$630K2.03N/AN/AN/A∞ENSCEnsysce Biosciences$5.21M0.92N/AN/A$2.59 per share0.78MBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/AMYNZMainz Biomed$890K5.53N/AN/A$2.61 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLIFAppili Therapeutics-$2.80M-$0.02N/A∞N/AN/AN/A-203.73%N/AENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)MBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)Latest APLIF, MYNZ, ENSC, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2025N/AMYNZMainz Biomed-$2.80N/AN/AN/AN/AN/A5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLIFAppili TherapeuticsN/A0.140.14ENSCEnsysce BiosciencesN/A2.502.50MBIOMustang BioN/A1.341.34MYNZMainz Biomed0.141.321.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLIFAppili TherapeuticsN/AENSCEnsysce Biosciences5.63%MBIOMustang Bio9.95%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipAPLIFAppili Therapeutics11.84%ENSCEnsysce Biosciences7.90%MBIOMustang Bio0.21%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableENSCEnsysce Biosciences102.37 million2.18 millionNot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableMYNZMainz Biomed303.44 million2.81 millionNot OptionableAPLIF, MYNZ, ENSC, and MBIO HeadlinesRecent News About These CompaniesPromising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy RatingJune 11, 2025 | tipranks.comMainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finanznachrichten.deMainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von BauchspeicheldrüsenkrebsJune 10, 2025 | anlegerplus.deMainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectJune 10, 2025 | finance.yahoo.comMainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert ProjectJune 10, 2025 | quiverquant.comMainz Biomed N.V. Shareholders Approve Key Proposals at Annual MeetingJune 5, 2025 | tipranks.comMainz Biomed N.V. Secures $4 Million Through Securities OfferingMay 21, 2025 | tipranks.comMainz Biomed prices $4M securities offeringMay 20, 2025 | seekingalpha.comMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | investing.comMainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant AmendmentsMay 19, 2025 | quiverquant.comMainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and WarrantsMay 19, 2025 | globenewswire.comMainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekanntMay 16, 2025 | anlegerplus.deMainz Biomed wird bis Ende Sommer Update zur Darmkrebs-Screening-Studie gebenMay 16, 2025 | de.investing.comEQS-News: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekanntMay 16, 2025 | onvista.deMainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical StudyMay 16, 2025 | globenewswire.comMainz Biomed launches public offering of units and warrantsMay 16, 2025 | msn.comMainz Biomed kündigt Jahreshauptversammlung für den 2. Juni anMay 2, 2025 | de.investing.comMainz Biomed Prepares for June 2025 Annual General MeetingMay 2, 2025 | tipranks.comMainz Biomed gibt Technologiepartnerschaft mit EDX Medical Group bekanntApril 29, 2025 | anlegerplus.deMainz Biomed advances in FDA approval for CRC testApril 29, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLIF, MYNZ, ENSC, and MBIO Company DescriptionsAppili Therapeutics OTCMKTS:APLIF$0.01 0.00 (0.00%) As of 06/20/2025Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.Ensysce Biosciences NASDAQ:ENSC$2.02 -0.11 (-5.16%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.09 +0.07 (+3.47%) As of 06/20/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Mustang Bio NASDAQ:MBIO$1.05 -0.02 (-1.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.07 +0.02 (+1.52%) As of 06/20/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Mainz Biomed NASDAQ:MYNZ$1.43 -0.10 (-6.54%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.46 +0.03 (+2.38%) As of 06/20/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
